A view on drug resistance in cancer
Paper cited by one pathway page and one bottleneck page, indexed on Europe PMC as PubMed record 31723286 and published in Nature; the citing pages link this DOI, which is how the record was matched.
Overview
The problem of resistance to therapy in cancer is multifaceted. Here we take a reductionist approach to define and separate the key determinants of drug resistance, which include tumour burden and growth kinetics; tumour heterogeneity; physical barriers; the immune system and the microenvironment; undruggable cancer drivers; and the many consequences of applying therapeutic pressures. We propose four general solutions to drug resistance that are based on earlier detection of tumours permitting cancer interception; adaptive monitoring during therapy; the addition of novel drugs and improved pharmacological principles that result in deeper responses; and the identification of cancer cell dependencies by high-throughput synthetic lethality screens, integration of clinico-genomic data and computational modelling. These different approaches could eventually be synthesized for each tumour at any decision point and used to inform the choice of therapy.
Indexed on Europe PMC as PubMed record 31723286 (DOI 10.1038/s41586-019-1730-1). Matched by DOI alone: one pathway page and one bottleneck page cite this DOI among their external links (the pages are listed under Related), and this page was written so that the citation resolves inside OnCo. No figure has been checked by an editor.
One pathway page and one bottleneck page on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
- Matched to the citing OnCo records by DOI alone; the summary reproduces the Europe PMC abstract and no figure has been verified against the full paper.
Similar pages
not linked directly; found by shared links- TermEGFR C797S
Shares Resistance routes: how a blocked pathway comes back, Acquired resistance to every therapy.
- TermMET amplification (bypass resistance)
Shares Resistance routes: how a blocked pathway comes back, Acquired resistance to every therapy.
- TermHistologic transformation
Shares Resistance routes: how a blocked pathway comes back, Acquired resistance to every therapy.
- Key paperOstrem and Shokat: the hidden pocket that made KRAS G12C druggable
- TermESR1 mutation
Shares Resistance routes: how a blocked pathway comes back, Acquired resistance to every therapy.
- Key paperAUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation
- TermDrug efflux pumps (ABC transporters)
Shares Resistance routes: how a blocked pathway comes back, Acquired resistance to every therapy.
- PathwayDrug efflux pumps (ABC transporters)
Shares Resistance routes: how a blocked pathway comes back, Acquired resistance to every therapy.